MA52976A - Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations - Google Patents
Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisationsInfo
- Publication number
- MA52976A MA52976A MA052976A MA52976A MA52976A MA 52976 A MA52976 A MA 52976A MA 052976 A MA052976 A MA 052976A MA 52976 A MA52976 A MA 52976A MA 52976 A MA52976 A MA 52976A
- Authority
- MA
- Morocco
- Prior art keywords
- substituted
- tetrahydrothienopyridine derivatives
- derivatives
- substituted tetrahydrothienopyridine
- tetrahydrothienopyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862687068P | 2018-06-19 | 2018-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52976A true MA52976A (fr) | 2021-04-28 |
Family
ID=67841114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052976A MA52976A (fr) | 2018-06-19 | 2019-06-18 | Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12012417B2 (fr) |
| EP (2) | EP4169925A3 (fr) |
| JP (1) | JP7328260B2 (fr) |
| KR (1) | KR20210022645A (fr) |
| CN (1) | CN112313237A (fr) |
| AU (1) | AU2019291488B2 (fr) |
| BR (1) | BR112020025696A2 (fr) |
| CA (1) | CA3100957A1 (fr) |
| CL (1) | CL2020003248A1 (fr) |
| CR (1) | CR20200618A (fr) |
| CU (1) | CU20200100A7 (fr) |
| EA (1) | EA202190046A1 (fr) |
| EC (1) | ECSP20080995A (fr) |
| ES (1) | ES2941946T3 (fr) |
| IL (1) | IL279441B2 (fr) |
| JO (1) | JOP20200326A1 (fr) |
| MA (1) | MA52976A (fr) |
| MX (1) | MX2020013852A (fr) |
| PE (1) | PE20210097A1 (fr) |
| PH (1) | PH12020552185A1 (fr) |
| SA (1) | SA520420809B1 (fr) |
| SG (1) | SG11202012625PA (fr) |
| WO (1) | WO2019244047A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3663299B1 (fr) * | 2017-08-01 | 2023-03-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Composé bicyclique agissant en tant qu'inhibiteur de ror gamma |
| AU2019291488B2 (en) | 2018-06-19 | 2022-02-24 | Novartis Ag | N-substituted tetrahydrothienopyridine derivatives and uses thereof |
| USD1006154S1 (en) * | 2023-06-27 | 2023-11-28 | Qiongfang Mao | Cable crossover attachment |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US498178A (en) | 1893-05-23 | William valentine leonard | ||
| US54472A (en) | 1866-05-01 | Improved blacking-brush | ||
| US5807A (en) | 1848-09-26 | Brake fob cabs | ||
| US8766A (en) | 1852-02-24 | Appabatus for lightening vessels | ||
| US4656A (en) | 1846-07-24 | Improvement in potato-plows | ||
| US6344A (en) | 1849-04-17 | Driving-bobbin | ||
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| SK286662B6 (sk) | 1996-04-23 | 2009-03-05 | Vertex Pharmaceuticals Incorporated | Deriváty močoviny, farmaceutické prostriedky, ktoré ich obsahujú, a ich použitie ako inhibítorov aktivity IMPDH enzýmu |
| ES2201452T3 (es) | 1997-03-14 | 2004-03-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de la enzima impdh. |
| EP1964561A1 (fr) | 1999-03-19 | 2008-09-03 | Vertex Pharmaceuticals Incorporated | Inhibiteurs d'enzyme IMPDH |
| GB0114185D0 (en) | 2001-06-12 | 2001-08-01 | Protherics Molecular Design Lt | Compounds |
| CZ20033163A3 (cs) | 2001-05-21 | 2004-08-18 | Monsantoátechnologyállc | Pesticidní koncentráty obsahující etheraminová povrchově aktivní činidla |
| US20030232994A1 (en) | 2001-10-04 | 2003-12-18 | Shao-Po Lu | Bicyclic thiophene derivatives and combinatorial libraries thereof |
| EP1538903A2 (fr) | 2002-09-12 | 2005-06-15 | Merck & Co., Inc. | Methode de traitement du diabete et d'etats associes |
| US7138529B2 (en) | 2003-04-16 | 2006-11-21 | Hoffmann-La Roche Inc. | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists |
| GB0324653D0 (en) | 2003-10-22 | 2003-11-26 | Syngenta Participations Ag | Fungicides |
| SI1753512T1 (sl) | 2004-05-28 | 2008-12-31 | 4Sc Ag | Tetrahidropiridotiofeni |
| JP2008509927A (ja) | 2004-08-12 | 2008-04-03 | ワイス | Ｇｄｆ−８阻害剤を使用する、糖尿病、肥満、および心臓血管疾患のための併用療法 |
| JP2008529989A (ja) | 2005-02-09 | 2008-08-07 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌のような増殖性の疾病の治療用のテトラヒドロピリドチオフェン |
| JP2008530053A (ja) | 2005-02-11 | 2008-08-07 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の治療のための抗増殖性剤としてのテトラヒドロピリドチオフェン |
| KR20080016597A (ko) | 2005-05-13 | 2008-02-21 | 바이로켐 파마 인코포레이티드 | 플라비바이러스 감염의 예방 또는 치료용 화합물 및 그의예방 또는 치료 방법 |
| EP1893618A2 (fr) | 2005-05-25 | 2008-03-05 | Nycomed GmbH | Tetrahydropyridothiophenes utilisés dans le traitement anticancereux |
| EP1896484A2 (fr) | 2005-05-25 | 2008-03-12 | Nycomed GmbH | Tetrahydropyridothiophenes utilisés dans le traitement anticancereux |
| EP1942110A4 (fr) | 2005-09-08 | 2010-08-04 | Zhejiang Huahai Pharm Co Ltd | Préparation de clopidogrel et ses composés analogues à base d'acétate de méthyl tétrahydrothiénopyridine |
| US20100285149A1 (en) | 2006-08-16 | 2010-11-11 | Klaus Pekari | Novel tetrahydropyridothiophenes |
| CA2660604A1 (fr) | 2006-08-16 | 2008-02-21 | 4Sc Ag | Derives de tetrahydrobenzothiophene |
| AU2007325315A1 (en) | 2006-11-28 | 2008-06-05 | Kalypsys Inc | Heterocyclic modulators of TGR5 |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20130129677A1 (en) | 2009-02-27 | 2013-05-23 | Siga Technologies, Inc. | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections |
| CA2753421A1 (fr) | 2009-02-27 | 2010-09-02 | Siga Technologies, Inc. | Derives de thienopyridine pour le traitement et la prevention d'infections par le virus de la dengue |
| JP5701655B2 (ja) | 2011-03-29 | 2015-04-15 | 奈良県 | 植物精油中のトロポロン類及び／又はフェノール類の金属錯体化方法 |
| BR112014007599A2 (pt) | 2011-09-30 | 2017-04-11 | Kineta Inc | compostos anti-virais |
| EP3325473A4 (fr) | 2015-07-22 | 2019-06-26 | The Royal Institution for the Advancement of Learning / McGill University | Composés et leurs utilisations dans le traitement de cancers et d'autres états médicaux |
| CN108689987A (zh) * | 2017-04-05 | 2018-10-23 | 浙江海正药业股份有限公司 | 一种磺胺类衍生物及其制备方法和用途 |
| US11053196B2 (en) | 2017-05-22 | 2021-07-06 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| EP3663299B1 (fr) | 2017-08-01 | 2023-03-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Composé bicyclique agissant en tant qu'inhibiteur de ror gamma |
| CN108191885B (zh) * | 2018-01-29 | 2020-08-04 | 华东师范大学 | 一类哌啶并噻吩类小分子有机化合物及其应用 |
| AU2019291488B2 (en) | 2018-06-19 | 2022-02-24 | Novartis Ag | N-substituted tetrahydrothienopyridine derivatives and uses thereof |
-
2019
- 2019-06-18 AU AU2019291488A patent/AU2019291488B2/en active Active
- 2019-06-18 EP EP22207844.6A patent/EP4169925A3/fr active Pending
- 2019-06-18 CN CN201980040348.4A patent/CN112313237A/zh active Pending
- 2019-06-18 CA CA3100957A patent/CA3100957A1/fr active Pending
- 2019-06-18 WO PCT/IB2019/055121 patent/WO2019244047A1/fr active Application Filing
- 2019-06-18 EA EA202190046A patent/EA202190046A1/ru unknown
- 2019-06-18 MX MX2020013852A patent/MX2020013852A/es unknown
- 2019-06-18 SG SG11202012625PA patent/SG11202012625PA/en unknown
- 2019-06-18 JO JOP/2020/0326A patent/JOP20200326A1/ar unknown
- 2019-06-18 CR CR20200618A patent/CR20200618A/es unknown
- 2019-06-18 PE PE2020002060A patent/PE20210097A1/es unknown
- 2019-06-18 ES ES19762467T patent/ES2941946T3/es active Active
- 2019-06-18 KR KR1020217001077A patent/KR20210022645A/ko not_active Application Discontinuation
- 2019-06-18 JP JP2020570065A patent/JP7328260B2/ja active Active
- 2019-06-18 EP EP19762467.9A patent/EP3810613B1/fr active Active
- 2019-06-18 CU CU2020000100A patent/CU20200100A7/es unknown
- 2019-06-18 BR BR112020025696-0A patent/BR112020025696A2/pt unknown
- 2019-06-18 US US17/253,755 patent/US12012417B2/en active Active
- 2019-06-18 MA MA052976A patent/MA52976A/fr unknown
-
2020
- 2020-12-14 IL IL279441A patent/IL279441B2/en unknown
- 2020-12-15 EC ECSENADI202080995A patent/ECSP20080995A/es unknown
- 2020-12-15 SA SA520420809A patent/SA520420809B1/ar unknown
- 2020-12-15 CL CL2020003248A patent/CL2020003248A1/es unknown
- 2020-12-16 PH PH12020552185A patent/PH12020552185A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12020552185A1 (en) | 2021-06-07 |
| WO2019244047A1 (fr) | 2019-12-26 |
| CU20200100A7 (es) | 2021-08-06 |
| IL279441A (en) | 2021-01-31 |
| JP2021529159A (ja) | 2021-10-28 |
| CR20200618A (es) | 2021-01-21 |
| EA202190046A1 (ru) | 2021-03-24 |
| KR20210022645A (ko) | 2021-03-03 |
| CL2020003248A1 (es) | 2021-07-09 |
| EP4169925A3 (fr) | 2023-06-14 |
| US20220073535A1 (en) | 2022-03-10 |
| US12012417B2 (en) | 2024-06-18 |
| EP3810613B1 (fr) | 2023-01-11 |
| SA520420809B1 (ar) | 2022-08-17 |
| ES2941946T3 (es) | 2023-05-26 |
| EP3810613A1 (fr) | 2021-04-28 |
| PE20210097A1 (es) | 2021-01-12 |
| AU2019291488A1 (en) | 2021-02-04 |
| CA3100957A1 (fr) | 2019-12-26 |
| CN112313237A (zh) | 2021-02-02 |
| ECSP20080995A (es) | 2021-02-26 |
| SG11202012625PA (en) | 2021-01-28 |
| EP4169925A2 (fr) | 2023-04-26 |
| AU2019291488B2 (en) | 2022-02-24 |
| BR112020025696A2 (pt) | 2021-03-16 |
| JP7328260B2 (ja) | 2023-08-16 |
| MX2020013852A (es) | 2021-05-27 |
| IL279441B2 (en) | 2023-06-01 |
| JOP20200326A1 (ar) | 2020-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52483A (fr) | Dérivés de gip et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA49952A (fr) | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations | |
| MA55565A (fr) | Agents de dégradation de stat et leurs utilisations | |
| MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
| MA52414A (fr) | Anticorps agonistes de pd-1 et leurs utilisations | |
| MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA48861A (fr) | Améliorations pharmacocinétiques de chélates bifonctionnels et leurs utilisations | |
| MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
| MA50173A (fr) | Composés activateurs de bisamide sarcomère et leurs utilisations | |
| MA50413A (fr) | Dérivés de benzimidazole et leurs utilisations | |
| MA56462A (fr) | Inhibiteurs de hpk1 et leurs utilisations | |
| MA52411A (fr) | Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| MA55083A (fr) | Polyribonucléotides et leurs utilisations cosmétiques | |
| MA54051A (fr) | Dérivés de pyridinyl sulfonamide, compositions pharmaceutiques et leurs utilisations | |
| MA52365A (fr) | Composés et leurs utilisations | |
| MA46945A (fr) | Exopolysaccharides et leurs utilisations | |
| DK3625224T3 (da) | N-substituerede indolderivater | |
| MA55385A (fr) | Composés et leurs utilisations |